Recently, several studies showed that the tumor imaging biomarkers could provide a promising way to predict the immune phenotype of tumors and to infer clinical outcomes for patients with cancer who had been treated with PD-1 and PD-L1 inhibitor (15, 16). The gene discussed is CD274; the disease is cancer.